Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236469 | 0.85 | PLA2G2A (0.56) | PLA2G2AKMT2A | |
| SCHEMBL344898 | 0.80 | PLA2G2A (0.69) | PLA2G2APLA2G1B | |
| SCHEMBL337567 | 0.78 | PLA2G2A (0.61) | PLA2G2APLA2G1B | |
| SCHEMBL8235994 | 0.78 | PLA2G2A (0.67) | PLA2G2ATSHRMAPK1KMT2APLA2G1B | |
| SCHEMBL7696968 | 0.76 | PLA2G2A (0.74) | PLA2G2APLA2G1B | |
| SCHEMBL7694912 | 0.76 | PLA2G2A (0.77) | PLA2G2APLA2G1B | |
| SCHEMBL7965041 | 0.74 | PLA2G2A (0.80) | PLA2G2APLA2G1B | |
| SCHEMBL10050594 | 0.73 | PLA2G2A (0.58) | PLA2G2ATSHRMAPK1KMT2APLA2G1B | |
| SCHEMBL7699729 | 0.73 | PLA2G2A (0.67) | PLA2G2ATSHRMAPK1KMT2APLA2G1B | |
| SCHEMBL344897 | 0.73 | PLA2G2A (0.84) | PLA2G2APLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | S1PR1, S1PR2, S1PR3 | PLA2G2A 630/4885TSHR 213/4885MAPK1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.